Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Regeneron Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Dose escalation cohorts: Patients with histologically or cytologically confirmed diagnosis of malignancy (including lymphoma) with demonstrated progression of a tumor for whom there is no available therapy likely to convey clinical benefit AND who have not been previously treated with a PD-1/PD-L1 inhibitor. These patients do not require measurable disease
Dose expansion cohorts: Patients with histologically or cytologically confirmed diagnosis of 1 of specified tumors with measurable disease per RECIST 1.1 or Lugano criteria. Some patients may have been previously treated with a PD-1 or PD-L1 inhibitor
Eastern Cooperative Oncology Group performance status of 0 or 1
Adequate organ and bone marrow function
You may not be if
Prior treatment with any LAG-3 targeting biologic or small molecule
Radiation therapy within 2 weeks prior to randomization and not recovered to baseline from any AE due to radiation
Untreated or active central nervous system metastases - Ongoing or recent (within 5 years) evidence of significant autoimmune disease
Corticosteroid therapy (\>10 mg prednisone/day or equivalent) within 1 week prior to the first dose of study drug
Myocardial infarction within 6 months
Clareo Health | Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
